期刊文献+

腺病毒载体纯化及在肿瘤基因治疗中的应用 被引量:9

Purification and application of adenoviral vectors in tumor gene therapy
下载PDF
导出
摘要 腺病毒是一种线性无包膜的双链DNA病毒,用于载体构建的主要是人类2型和5型腺病毒。现在通过对腺病毒的改造,已经成功构建出第一代、第二代、第三代和条件复制型腺病毒载体。随着腺病毒载体在蛋白质表达中的广泛使用,对高产量、高纯度腺病毒载体的需求量逐渐增大,因此近年来在传统纯化腺病毒载体的基础上发展出各种纯化新方法。同时,由于腺病毒载体自身的一些优点,使其在疫苗和肿瘤基因治疗中也得到了较为广泛的应用。 Adenoviruses(Ad) are non-enveloped,double-stranded DNA viruses.Ad serotype 2(Ad2) and Ad5 are mainly used to construct Ad vectors(Advs).The first,second,and third generations of Advs and the conditionally replicating Adv have been successfully constructed.A wide use of the recombinant Adv for protein expression accelerates the requirement of high yields and purity of Advs.Recently various novel purification methods based on traditional methods have been developed.Meanwhile several advantages of Advs have made them extensively applicable in vaccine and tumor gene therapies.
出处 《医学研究生学报》 CAS 2009年第12期1324-1327,1332,共5页 Journal of Medical Postgraduates
基金 江苏省科教兴卫医学重点人才基金课题(批准号:RC2007117) 南京军区医药卫生科研项目重点课题(批准号:07Z032)
关键词 腺病毒载体 纯化 基因治疗 疫苗 Adenoviral vector Purification Gene therapy Vaccine
  • 相关文献

参考文献8

二级参考文献139

共引文献60

同被引文献67

  • 1Bo Li, Xing-Hua Gou, Lin Chen, De-Hua Li, Yong-Heng Zhao, Lei Han, Lan-Ying Zhao and Jian-ping Gong Department of Hepatobiliary Surgery, Second Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing 400010, China Genetic Engineering Laboratory, Chengdu Diao Group Co. Ltd., Chengdu 610041, China and Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.Construction of the recombinant adenovirus vector carrying antisense multidrug resistance gene[J].Hepatobiliary & Pancreatic Diseases International,2006,5(1):80-84. 被引量:6
  • 2唐树温,张林,王先升,戴翔.重组腺病毒p53在肿瘤基因治疗中的应用[J].山东医药,2005,45(26):75-76. 被引量:1
  • 3张建军(综述),钱关祥(审校),葛盛芳(审校).肿瘤基因治疗的腺病毒策略[J].肿瘤研究与临床,2007,19(1):63-65. 被引量:4
  • 4Kimberley FC,Sivasankar B,Paul Morgan B.Alternative roles for CD59[J].Mol Immunol,2007,44(1-3):73-81.
  • 5Bachmann MF,Barner M,Kopf M.CD2 sets quantitative thresholds in T cell activation[J].J Exp Med,1999,190:1383-1392.
  • 6Hahn WC,Menu E,Bothwell AL,et al.Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59[J].Science,1992,256(5065):1805-1807.
  • 7Hahn WC,Burakoff SJ,Bierer BE.Signal transduction pathways involved in T cell receptor-induced regulation of CD2 avidity for CD58[J].J Immunol,1993,150(7):2607-2619.
  • 8Deckert M,Kubar J,Zoccola D,et al.CD59 molecule:a second ligand for CD2 in T cell adhesion[J].Eur J Immunol,1992,22(11):2943-2947.
  • 9Verhagen AM,Schraven B,Wild M,et al.Differential interaction of the CD2 extracellular and intracellular domains with the tyrosine phosphatase CD45 and the zeta chain of the TCR/CD3/zeta complex[J].Eur J Immunol,1996,26 (12):2841-2849.
  • 10Deckert M,Ticchioni M,Mari B,et al.The glycosylphosphatidylinositol-anchored CD59 protein stimulates both T cell receptor zeta/ZAP-70-dependent and -independent signaling pathways in T cells[J].Eur J Immunol,1995,25(7):1815-1822.

引证文献9

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部